WuXi Biologics Partners with Sino Biopharmaceutical for First-in-Class Monoclonal Antibody Development
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a...
Company
GenFleet Therapeutics Submits IPO Application to HKEX, Backed by CITIC Securities
On December 27, 2024, GenFleet Therapeutics, a biopharmaceutical company based in Shanghai, submitted its application...
Overwhelming Shareholder Support for Hengrui Pharmaceuticals’ H-Share IPO
On December 26, Hengrui Pharmaceuticals (SHA: 600276) held its second extraordinary general meeting of 2024,...
Dynamiker Biotechnology Receives Approval for IPO on Beijing Stock Exchange
On December 27, 2024, the official website of the Beijing Stock Exchange announced that Dynamiker...
MicroPort Endovascular MedTech’s Castor® Branched Stent Wins China Patent Gold Award
The National Intellectual Property Administration has announced the winners of the 25th China Patent Awards,...
Daiichi Sankyo and AstraZeneca Withdraw EU Application for Datopotamab Deruxtecan in Lung Cancer
Partners Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) have jointly announced the voluntary...
AstraZeneca China Announces Structural Adjustments to Oncology Business Divisions
UK major AstraZeneca’s (AZ, NASDAQ: AZN) China unit has announced a new round of structural...
Beijing Releases List of Novel Drugs and Technologies Exempt from CHS-DRG Payment Scheme
The Beijing Municipal Medical Insurance Bureau has released the list of the first batch of...
Johnson & Johnson Secures Licensing Deal with Kaken Pharmaceutical for STAT6 Program
US giant Johnson & Johnson (J&J, NYSE: JNJ) has announced an exclusive licensing agreement with...
Ascentage Pharma Announces Secondary Offering on Nasdaq, Expanding Global Reach
China-based Ascentage Pharma (HKG: 6855) has unveiled plans for a secondary offering of up to...
Auzone Submits NDA for Oral Edaravone TTYP01 to Treat ALS
Auzone Biological Technology has announced the submission of a New Drug Application (NDA) for its...
Pediatrix Therapeutics’ Neffy NDA Accepted by NMPA for Allergy Treatment
China-based Pediatrix Therapeutics has announced that the New Drug Application (NDA) for its neffy (epinephrine...
Immunochina Pharmaceuticals and Cell Store Partner to Advance Cell Therapy Commercialization in China
Beijing-based firms Immunochina Pharmaceuticals and Cell Store have announced a strategic partnership aimed at bolstering...
Hinova Pharmaceuticals Enrolls First Patient in Phase II Study for HP518 in mCRPC
China-based biopharma Hinova Pharmaceuticals has announced the enrollment of the first patient in an open,...
Xbiome Partners with ZoHealth to Advance Microbiome Drug Development and Precision Nutrition
China-based Xbiome, an AI-driven microbiome drug development company, has announced a strategic alliance with Australia-headquartered...
Astellas Pharma Partners with Axcelead DDP for Targeted Protein Degraders Discovery
Japan-based Astellas Pharma Inc. (TYO: 4503) has struck an accord with compatriot firm Axcelead Drug...
AusperBio Secures $73 Million in Series B Financing to Advance Hepatitis B Therapy
Sino-US liver therapy developer AusperBio has announced the completion of a USD 73 million Series...
Advaccine Biotechnology’s MICROEPAD Receives FDA Registration Approval
China-based vaccine developer Advaccine Biotechnology has announced receiving registration approval from the US Food and...
Shandong Buchang Pharmaceuticals Terminates Agreement with NOVAST Laboratories
China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) has announced the termination of the development,...
Chia Tai Tianqing’s Benmelstobart and Anlotinib Combo Meets Primary Endpoint in Phase III Study
China-based Chia Tai Tianqing Pharmaceutical, a subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177), has announced...